摘要
目的探讨血清肿瘤标记物癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、细胞角蛋白19片段抗原(CYFRA21-1)联合检测在非小细胞肺癌(NSCLC)早期诊断中的应用价值,旨在为NSCLC的诊治提供理论参考。方法采用电化学免疫发光法(ECLIA)测定102例NSCLC患者、97例正常健康者的3种肿瘤标志物(CEA、NSE、CYFRA21-1)水平。结果肺癌组CEA、NSE、CYFRA21-1的水平分别为6.81 ng/ml、11.55 ng/ml及5.63 ng/ml,显著高于对照组的2.02 ng/ml、6.47 ng/ml及2.12 ng/ml(P<0.05);CEA、NSE、CYFRA21-1在NSCLC诊断中的均具有较高的特异性(分别为95.9%、100.0%、94.8%),但敏感性均较低(59.8%、26.5%、44.1%)。而此3种肿瘤标志物联合检测在NSCLC诊断中有较高的敏感性和特异性,分别为96.1%和86.6%。结论血清CEA、NSE、CYFRA21-1联合检测可以提高NSCLC诊断的敏感性,对NSCLC的早期诊断和治疗具有重要的临床价值。
Objective To investigate the diagnostic value of serum tumor bio-marker CEA, NSE and CYFRA21-1 joint detection in early diagnosis of non-small cell lung cancer （NSCLC）, and to provide theoretical reference for diagnosis and treatment of NSCLC. Methods The three serum tumor biomarkers （CEA, NSE and CYFRA21-1） level of 102 cases of patients with NSCLC and 97 healthy people were determined by ECLIA. Results The three serum markers of lung cancer group were significantly higher than that of the normal control group （P〈 0.05）. The sensitivity of CEA, NSE and CYFRA21-1 in the diagnosis of NSCLC were low and the specificity of CEA, NSE and CYFRA21-1 diagnosis in NSCLC were high. The three tumor markers combined detection had higher sensitivity and specificity in the early diagnosis of NSCLC. The sensitivity and specificity were 96.1% and 86.6% respectively. Conclusion The three tumor markers （CEA, NSE and CYFRA21-1） combined detection can improve the sensitivity in early diagnosis of NSCLC. It has important clinical value for the early diagnosis and treatment of NSCLC.
出处
《北京医学》
CAS
2014年第7期578-580,共3页
Beijing Medical Journal
关键词
非小细胞肺癌
肿瘤标记物
联合检测
Non-small cell lung cancer
Tumor markers
Joint detection
